Narayana Hrudayalaya (NH) Q1 26/27 earnings summary

Executive summary

• Achieved consolidated operating revenue of ₹26,836 million in Q1 FY27, up 78% year-over-year, with EBITDA at ₹5,052 million (18.8% margin) and PAT at ₹2,073 million (7.7% margin).

• India hospitals delivered 40% EBITDA growth, driven by high-end procedures and increased footfalls, while clinics contributed significantly to OPD footfalls and brand strength.

• Significant operational expansion included advanced robotic and minimally invasive procedures and digital transformation initiatives.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed and approved by the Board and Audit Committee, with auditors expressing an unmodified review conclusion.

• Integrated care model and insurance business are early-stage but showing positive ecosystem effects.

Financial highlights

• India business EBITDA margin expanded by 400 bps year-over-year, reaching 24.8% in Q1 FY27; consolidated EBITDA margin at 18.8%.

• Cayman Hospital margins returned to optimal levels, with insurance losses reduced sequentially from $5.2 million to $3.7 million; Cayman Islands hospital revenue was US$44.8 million (+5.1% YoY, -9.6% QoQ).

• U.K. business saw a 5% year-over-year revenue growth, but sequential revenue and margin decline due to operational disruptions from a heatwave; UK hospital revenue was GBP 65.0 million (-3.8% QoQ), EBITDA margin post-IFRS at 8.8%.

• Standalone revenue from operations was ₹10,971 million, up from ₹9,431 million year-over-year; standalone net profit for the quarter was ₹1,379 million.

• Net debt to equity ratio at 0.42 as of June 30, 2026; consolidated debt-equity ratio stood at 1.24.

Outlook and guidance

• No major bed additions planned for the next 2-3 years, but ongoing expansion with bed capacity targeted to exceed 7,600 by FY30; focus remains on leveraging existing assets and expanding clinics.

• Multiple greenfield and lease projects underway in Bangalore, Kolkata, and Raipur, with phased completions through FY30.

• Margin trajectory expected to improve as integration costs normalize and insurance/clinic losses are recouped.

• U.K. business expected to improve payer mix and margins over 4-5 years, with early signs of progress.

• Ongoing regulatory and merger activities are expected to shape future operations.